

# A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Sanofi
<b>Enrollment</b>	160 participants

## Key Eligibility Criteria

---

### Inclusion (13)

- Participants are eligible to be included in the study only if all of the following criteria apply:
- Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).
- Participant must have either typical CIDP, or one of the following 2 CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the study adjudication committee.
- Participants must have responded to IVIg in the past 5 years.
- Participant must be on a stable maintenance dosage of IVIg.
- ... and 8 more (see full listing online)

### Exclusion (34)

- Participants are excluded from the study if any of the following criteria apply:
- Polyneuropathy of other causes, including but not limited to acute demyelinating polyneuropathies (eg, Guillain-Barré syndrome), hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS syndrome, lumbosacral radiculoplexus neuropathy.
- Sensory CIDP, distal CIDP and focal CIDP variants.
- Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments.
- Poorly controlled diabetes
- ... and 29 more (see full listing online)

## Locations (113 total)

---

Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama, United States  
Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014, Scottsdale, Arizona, United States  
Keck School of Medicine of University of Southern California- Site Number : 8400002, Los Angeles, California, United States  
... and 110 more locations

---

<https://clinicaltrials.gov/study/NCT06290141>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.